BPC-157 + KPV is a two-peptide vendor product that pairs a stable gastric pentadecapeptide studied for cytoprotection and tissue repair with the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory signalling. Researchers look at the pairing because the two components are described in separate literatures that both centre on the gut mucosa and on injury-associated inflammation. This monograph covers each component's evidence and the fact that the combination itself has not been studied.
The product contains two distinct peptides: BPC-157, a synthetic 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) corresponding to a partial fragment of a protein identified in human gastric juice [1], and KPV, the tripeptide Lys-Pro-Val, which is the C-terminal three-residue fragment of α-MSH [2]. There is no single molecular weight or formula for the product; each peptide keeps its own identity and must be verified separately. The listings currently tracked in VialTalk's catalog for this blend are encapsulated products rather than lyophilized vials; VialTalk does not reproduce per-unit amounts. The proportion of each peptide in a given product is set by the vendor and is not standardised across the market.
BPC-157. The mechanisms described in the literature are hypothesised rather than settled; the most consistently reported are promotion of angiogenesis via the VEGFR2 pathway and modulation of the nitric oxide system [1]. A 2025 narrative review describes overlapping pathways including VEGFR2, Akt-eNOS nitric oxide signalling and ERK1/2, and characterises the compound's effects as angiogenic, fibroblast-activating and anti-inflammatory in animal models [3]. In cultured rat tendon fibroblasts, BPC-157 did not directly increase proliferation but increased cell survival under oxidative stress, cell migration and spreading, with increased FAK and paxillin phosphorylation [4]. A 2026 cell-based study reported that intracellular BPC-157 engages the E3 ligase adaptor FBXO22, stabilising the transcription factor BACH1 and enhancing vascular-regeneration processes [5].
KPV. KPV is reported to carry the anti-inflammatory activity of the parent α-MSH peptide without the pigmentation effects [2]. In immortalised human bronchial epithelial cells, KPV inhibited NF-κB signalling and IL-8 and eotaxin secretion; the effect was associated with nuclear import of KPV, IκBα stabilisation and suppressed nuclear translocation of the p65RelA subunit — consistent with an intracellular mode of action [6]. In a rat TNBS colitis model, KPV delivered in a mucosa-adherent hydrogel alleviated colitis and supported recovery of the epithelial barrier [7].
The rationale for pairing them. Both literatures converge on gastrointestinal mucosal injury and inflammation: BPC-157 through cytoprotection and repair-associated angiogenesis [1][3], KPV through suppression of NF-κB-driven inflammatory signalling [6][7]. This is a hypothesis, not evidence of additive or synergistic action.
No study of BPC-157 and KPV given together was found. A PubMed search combining the two names (BPC-157/BPC 157/BPC157 with KPV/Lys-Pro-Val) returned a single record: a 2026 review of the FDA Pharmacy Compounding Advisory Committee's evaluation of synthetic peptides, which lists BPC-157 and KPV among the compounds discussed — it is a regulatory review, not a combination experiment [12]. The VialTalk research library holds one document addressing the three-way pairing of KPV, BPC-157 and TB-500; it is an OSF-posted synthesis project, not peer-reviewed experimental work, and its own description states that each peptide has been studied independently in preclinical contexts [11].
Each component's own evidence base is thin in humans:
The published work covers each peptide only on its own [1][2][11]. Nothing is known about pharmacokinetic interaction, stability of the two peptides in a shared formulation, or whether either alters the other's activity. Any claim that the pair outperforms either component alone is unsupported.
Each component has been studied separately in gut and mucosal-inflammation models [1][2]. It is a reduced form of the three-peptide BPC-157 + TB-500 + KPV blend, without TB-500. Neither blend has been studied as a fixed combination.
Follow the vendor's storage statement for the product format; keep peptide material sealed, dry, cool and protected from light. A blend is only as stable as its least-stable component, so default to the more conservative storage window of the two.
A meaningful COA for this product must confirm identity of both peptides by mass spectrometry and report purity for each by HPLC — a single "blend purity" line does not show that both are present. BPC-157 sequence-incorrect and under-filled product is a known market problem [1]; KPV, as a simple tripeptide, is straightforward to verify [2]. Demand a per-component content breakdown, not just a total. For capsules, the COA should state whether the finished product or the raw peptide was tested.
[1] VialTalk monograph — BPC-157 — https://vialtalk.com/forum/peptide-research-library/bpc-157-research-monograph-structure-mechanism-evidence
[2] VialTalk monograph — KPV — https://vialtalk.com/forum/peptide-research-library/kpv-research-monograph-alpha-msh-tripeptide-anti-inflammatory
[3] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (2025) — https://pubmed.ncbi.nlm.nih.gov/40789979/
[4] BPC 157 tendon healing: outgrowth, cell survival and migration (rat tendon fibroblasts) — https://pubmed.ncbi.nlm.nih.gov/21030672/
[5] BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1 (2026) — https://pubmed.ncbi.nlm.nih.gov/41606641/
[6] Mechanism of KPV action in human bronchial epithelial cells — https://pubmed.ncbi.nlm.nih.gov/22837805/
[7] A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon — https://pubmed.ncbi.nlm.nih.gov/35245681/
[8] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
[9] BPC-157 human safety pilot study, two participants (2025) — https://pubmed.ncbi.nlm.nih.gov/40131143/
[10] NCT07437547 — BPC 157 for hamstring strain (Phase 2, recruiting) — https://clinicaltrials.gov/study/NCT07437547
[11] Precision Micro-Peptides: KPV, BPC-157 and TB-500 (OSF project) — https://doi.org/10.17605/osf.io/kypv3
[12] Willis & Vu, Int J Pharm Compd 2026 — Synthetic Peptides in Pharmacy Compounding — https://pubmed.ncbi.nlm.nih.gov/42752426/
Research-use note: This monograph is an educational summary of the published literature on BPC-157 and KPV. The fixed BPC-157 + KPV combination has not been studied in any published human or animal study known to VialTalk, and neither peptide is an approved drug. Nothing here is medical advice or a usage recommendation.
